Induction cisplatin–irinotecan followed by concurrent cisplatin–irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial

A recent phase I study showed that weekly cisplatin, irinotecan and concurrent radiotherapy can be administered with moderate toxicity in patients with oesophageal cancer. Patients with no prior treatment and oesophageal cancer stage I to III, performance status <3, caloric intake >1500 kcal d...

Descripción completa

Detalles Bibliográficos
Autores principales: Michel, P, Adenis, A, Fiore, F Di, Boucher, E, Galais, M P, Dahan, L, Mirabel, X, Hamidou, H, Raoul, J L, Jacob, J H, Hellot, M F, Prod'Homme, S, Paillot, B
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360517/
https://www.ncbi.nlm.nih.gov/pubmed/16967056
http://dx.doi.org/10.1038/sj.bjc.6603328

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360517/
https://www.ncbi.nlm.nih.gov/pubmed/16967056
http://dx.doi.org/10.1038/sj.bjc.6603328

Ejemplares similares